Test–Retest Reproducibility of 18F-MPPF PET in Healthy Humans: A Reliability Study

The aim of this study was to assess the reliability of 2′-methoxyphenyl-(N-2′-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine (18F-MPPF) PET binding parameter's quantification via a test–retest study over a long-term period. Methods: Ten healthy volunteers underwent 2 dynamic 18F-MPPF PET scans in an interval of 6 mo. As a methodologic control, 10 simulated datasets, including interindividual functional and anatomic variabilities, were also used to assess the measurement variations in the absence of intraindividual variability. Indices of tracer binding were computed using 2 different models: (a) the simplified reference tissue model (SRTM) and (b) the Logan graphical model. The SRTM allows computing the binding potential (BP) index and plasma-to-brain transport constants (R1, k2). The Logan model evaluates the distribution volume (DV). For both methods, cerebellum was taken as the reference region. From both models, binding indices were calculated with time–activity curves extracted from regions of interest, on one hand, and for each voxel to perform parametric images on the other hand. Results: Reliability indices—that is, bias, variability, and intraclass correlation (ICC)—indicated a good reproducibility: the BP percentage change in mean between test and retest is close to 1% in rich regions and 2% in poor regions. The typical error is around 7%. Mean ICC is over 0.70. The DV percentage change in the mean is ±2.5%, with a typical error close to 6% and an ICC over 0.60. Conclusion: Our results show a good reliability, with a reasonable level of intraindividual biologic variability that allows crossover studies with 18F-MPPF in which small percentage changes are expected between test and retest measurements, in group studies and for single subject assessment.

[1]  Luc Zimmer,et al.  [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain , 2007, Neuropharmacology.

[2]  Kjell Någren,et al.  Measurement of Serotonin 5-HT1A Receptor Binding Using Positron Emission Tomography and [carbonyl-11C]WAY-100635—Considerations on the Validity of Cerebellum as a Reference Region , 2007 .

[3]  Mark Slifstein,et al.  Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  J. Logan Graphical analysis of PET data applied to reversible and irreversible tracers. , 1999, Nuclear medicine and biology.

[5]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[6]  Chester A. Mathis,et al.  Gender-specific aging effects on the serotonin 1A receptor , 2001, Brain Research.

[7]  D Comar,et al.  High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. , 1998, Nuclear medicine and biology.

[8]  Alan A. Wilson,et al.  Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor–treated depression: An [18F] MPPF positron emission tomography study , 2004, Biological Psychiatry.

[9]  D. Goldberg,et al.  A scaled version of the General Health Questionnaire , 1979, Psychological Medicine.

[10]  C. Lemaire,et al.  New automation of [18F]MPPF using a coincidence synthesizer , 2001 .

[11]  B. Jacobs,et al.  A Critical Review of 5-HT Brain Microdialysis and Behavior , 1997, Reviews in the neurosciences.

[12]  J. Passchier,et al.  Quantitative imaging of 5-HT(1A) receptor binding in healthy volunteers with [(18)f]p-MPPF. , 2000, Nuclear medicine and biology.

[13]  Alan C. Evans,et al.  Creation and Application of a Simulated Database of Dynamic [$^18$F]MPPF PET Acquisitions Incorporating Inter-Individual Anatomical and Biological Variability , 2006, IEEE Transactions on Medical Imaging.

[14]  Laurent Descarries,et al.  Toward brain imaging of serotonin 5-HT1A autoreceptor internalization , 2004, NeuroImage.

[15]  Laurent Descarries,et al.  Acute Treatment with the Antidepressant Fluoxetine Internalizes 5-HT1A Autoreceptors and Reduces the In Vivo Binding of the PET Radioligand [18F]MPPF in the Nucleus Raphe Dorsalis of Rat , 2004, The Journal of Neuroscience.

[16]  David C. Reutens,et al.  Increased serotonin receptor availability in human sleep: Evidence from an [18F]MPPF PET study in narcolepsy , 2006, NeuroImage.

[17]  François Mauguière,et al.  5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. , 2004, Brain : a journal of neurology.

[18]  Will G. Hopkins,et al.  A new view of statistics , 2002 .

[19]  M Slifstein,et al.  Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Anthonin Reilhac,et al.  A PET imaging study of 5-HT1A receptors in cat brain after acute and chronic fluoxetine treatment , 2006, NeuroImage.

[21]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[22]  Karl J. Friston,et al.  A unified statistical approach for determining significant signals in images of cerebral activation , 1996, Human brain mapping.

[23]  François Mauguière,et al.  Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG , 2004, NeuroImage.

[24]  G. W. Snedecor STATISTICAL METHODS , 1967 .

[25]  Masanori Ichise,et al.  PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  L. Lanfumey,et al.  5-HT1 receptors. , 2004, Current drug targets. CNS and neurological disorders.

[27]  Nicolas Costes,et al.  A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Robert B. Innis,et al.  Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin , 2001, Psychiatry Research: Neuroimaging.

[29]  R N Gunn,et al.  Quantitative analysis of [carbonyl-(11)C]WAY-100635 PET studies. , 2000, Nuclear medicine and biology.